An advisory panel for the U.S. Food and Drug Administration voted 6-3 against #AstraZeneca ’s oral drug #camizestrant intended for a type of breast cancer tumor, citing concerns around trial design. www.cnbc.com/2026/05/01/a...

AstraZeneca stock falls after ...